Subscribe
shutterstock_1827455255_henadzi_kllent
HENADZI KlLENT / Shutterstock.com
25 October 2022Big PharmaStaff Writer

Japanese firm acquires US drugmaker after increasing offer

The deal sees Sumitomo acquiring ownership of cancer and uterine fibroid treatments | Myovant initially rejected low offer that “undervalued” the company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit affirms Latuda decision in Sumitomo clash
19 April 2018   The US Court of Appeals for the Federal Circuit affirmed a lower court’s claim construction of a patent which covers Sunovion’s schizophrenia and bipolar depression drug Latuda on Monday, April 16.
Americas
Par Pharmaceutical in pre-emptive strike to protect Latuda generic
5 January 2017   Par Pharmaceutical has sought a declaratory judgment that it did not infringe patents belonging to Sumitomo and its subsidiary Sunovion that protect bipolar disorder drug Latuda.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Federal Circuit affirms Latuda decision in Sumitomo clash
19 April 2018   The US Court of Appeals for the Federal Circuit affirmed a lower court’s claim construction of a patent which covers Sunovion’s schizophrenia and bipolar depression drug Latuda on Monday, April 16.
Americas
Par Pharmaceutical in pre-emptive strike to protect Latuda generic
5 January 2017   Par Pharmaceutical has sought a declaratory judgment that it did not infringe patents belonging to Sumitomo and its subsidiary Sunovion that protect bipolar disorder drug Latuda.

More on this story

Americas
Federal Circuit affirms Latuda decision in Sumitomo clash
19 April 2018   The US Court of Appeals for the Federal Circuit affirmed a lower court’s claim construction of a patent which covers Sunovion’s schizophrenia and bipolar depression drug Latuda on Monday, April 16.
Americas
Par Pharmaceutical in pre-emptive strike to protect Latuda generic
5 January 2017   Par Pharmaceutical has sought a declaratory judgment that it did not infringe patents belonging to Sumitomo and its subsidiary Sunovion that protect bipolar disorder drug Latuda.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent